Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece

Current Medical Research and Opinion

Volumn 23, Issue 9, 2007, Pages 2251-2257

  Maniadakis, N ^a   Pallis, A ^a   Fragoulakis, V ^b   Prezerakos, P ^c   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b Health Economics Department   (Greece)

^c Centre of Educations and Specialisations   (Greece)

Author keywords

Colorectal cancer; Cost; Economic evaluation; Minimisation analysis

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COST MINIMIZATION ANALYSIS; DECISION MAKING; DRUG COST; ECONOMIC EVALUATION; FEMALE; GREECE; HEALTH CARE COST; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; COLORECTAL TUMOR; CONTROLLED STUDY; COST OF ILLNESS; ECONOMICS; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COST OF ILLNESS; FLUOROURACIL; GREECE; HUMANS; LEUCOVORIN; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 36048945087     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X223765     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. Ca Cancer J Clin 2005;55:74-108
2. Kohne CH, Schoffski P, Wilke H, et al. Effective biomodulation by leukovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998;16:418-26
3. Poon MA, O'Connel MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-18
4. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leukovorin and fluorouracil bolus with bimonthly high dose leukovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;14:808-15
5. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-82
6. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leukovorin for metastatic colorectal cancer. New Engl J Med 2000;343:905-14
7. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 2000;355:1041-47
8. Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053-71
9. de Gramont A, Figer A, Seymour M, et al. Leukovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47
10. Goldberg R, Sargent Dj, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30
11. Souglakos J, Mavroudis D, Kakolyris S, et al. A triplet combination with irinotecan (CPT-11) plus oxaliplatin (LOHP) plus continuous infusion 5-fluorouracil (5-FU) and leucovorin (LV) as first line treatment in metastatic colorectal cancer (MCC): a multicenter phase II trial. J Clin Oncol 2002;20:2661-7
12. Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002;20:4006-14
13. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) versus FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) as first line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94:798-805
14. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford University Press; 1997
15. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford University Press; 1996
16. Van Hout A, Maiwenn JA, Gordon GS, et al. Costs, effects and C/E ratios alongside a clinical trial. Health Econ 1994;3:309-19
17. Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 2005;8:1-2
18. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-6
19. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leukovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-14
20. Tappenden P, Jones R, Paisley S, et al. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007;11:1-6